TYP 4.76% 2.0¢ tryptamine therapeutics limited

Codiak ($800mil market capitalisation), page-158

  1. 1,216 Posts.
    lightbulb Created with Sketch. 1375
    Does anyone on this forum even understand what exosomes are? You do realise that no two exosomes are alike? How do you expect the FDA to ever approve such a heterogenous product. And how do you expect EX1 to determine the MOA? Its no good just isolating exosomes and seeing if they heal wounds. The real value is when EX1 can engineer exosomes, which is at least 10-15 years away to develop a product that can even be tested.

    FYI you lot are just paying for scientific research.
 
watchlist Created with Sketch. Add TYP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.